|
|
News Breaks
|
October 27, 2009
|
| 16:13 EDT |  | MMSI |
| theflyonthewall.com: | Merit Medical announces three-part deal with Vysera Biomedical | | The deal will give Merit access to certain intellectual property and know-how for valve technology, opportunities to commercialize certain biomaterial technology and equity ownership in Vysera. The transactions provide Merit with an exclusive license for certain valve technology that may be incorporated into non-vascular stents, specifically esophageal stents, to address acid reflux conditions. Secondly, the transactions provide Merit with an exclusive license for the development and use of certain biomaterial technology for the coating of selected non-vascular stents and gastrointestinal and drainage catheters. Finally, the transactions provide Merit with an equity investment of approximately $2.4M, which will give Merit an approximate 14.45% fully-diluted participating equity interest in Vysera. Additionally, Fred P. Lampropoulos, Merit's Chairman and CEO, has been elected as a director of Vysera. The total amount paid by Merit to Vysera in license fees and equity purchase payments is approximately $3.9M. :theflyonthewall.com |
|
|
News For MMSI From The Last 14 Days Check below for free stories on MMSI the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 7, 2012
|
| 14:48 EDT | | MMSI |
| theflyonthewall.com: | Merit Medical receives FDA warning letter | | Merit Medical Systems announced it received a warning letter from the FDA regarding modifications to the hydrophilic coating process for the Merit Laureate Hydrophilic Guidewire after an inspection of the company's facility in Galway, Ireland. The company intends to respond to the letter within 15 business days, as required by the FDA. Merit has already begun to resolve the issues that were raised. In the meantime, Merit's Irish facility remains fully functional for all other products. Merit's CEO said, "Officer. "The FDA warning letter applies only to the Merit Laureate, which represented less than 1% of Merit's total revenues for 2011." :theflyonthewall.com |
| | 09:33 EDT | | MMSI |
|
|
February 2, 2012
|
| 13:01 EDT | | MMSI |
|
|
February 1, 2012
|
| 09:32 EDT | | MMSI |
|
|
|
|
|
Subscribe for More Information